Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
301-320 of 1,738 trials

HER2-Positive Oligo-Metastatic Breast Cancer: T-DXd Treatment Study

We are investigating how well T-DXd works in combination with other treatments for patients with HER2-positive oligo-metastatic breast cancer. The study will also look at safety and how it affects cancer markers in the blood.

HER2-Positive Metastatic Breast Cancer6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Non-Seminomatous Germ-Cell Tumors: Personalized Treatment Study

We are exploring new treatment strategies for young adults with poor-prognosis non-seminomatous germ-cell tumors. This study aims to improve outcomes through personalized care and early assessments.

Germ Cell Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Spironolactone for Arrhythmogenic Right Ventricular Dysplasia (ARVD)

We are studying whether spironolactone can help reduce heart deterioration and arrhythmias in patients with ARVD. This trial compares its effects to a placebo over one and three years.

Arrhythmogenic Right Ventricular Dysplasia>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Multiple Myeloma: HyQvia for Infection Prevention

We are studying whether HyQvia can help reduce infections in patients with newly diagnosed multiple myeloma who are not eligible for a transplant. The trial aims to see if it improves survival and quality of life compared to standard care.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

Advanced Solid Tumors: Amivantamab Treatment Study

We are studying a new treatment called amivantamab for patients with advanced or metastatic solid tumors, including those with EGFR-mutated lung cancer. The goal is to see how well it works when combined with other therapies.

Non-small Cell Lung CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Extrapulmonary Small Cell Carcinoma: Durvalumab Combination Therapy

We are studying a new treatment combining durvalumab with carboplatin or cisplatin and etoposide for patients with extensive stage extrapulmonary small cell carcinoma. The goal is to see if this combination improves survival and quality of life compared to standard treatments.

Extensive Stage Extrapulmonary Small Cell CarcinomaEfficacy phase (II)No PlaceboStandard MedicinesOncology

ASP1570 for Advanced Solid Tumors

We are studying a new treatment, ASP1570, alone and with pembrolizumab for adults with advanced solid tumors. The trial aims to evaluate safety, tolerability, and potential anti-tumor effects.

Advanced Solid TumorsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Preclinical Alzheimer's Disease: JNJ-64042056 Immunotherapy

We are studying a new treatment to see if it may help slow cognitive decline in people with preclinical Alzheimer's disease. Participants will receive either the treatment or a placebo to compare effects.

Preclinical Alzheimer's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesNeurologyPsychiatry

Lung Cancer: Avutometinib and Sotorasib Study

We are testing a combination of two medications for patients with KRAS G12C mutant non-small cell lung cancer. The goal is to find the best dose and see how well it works and how safe it is.

Non-small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Colorectal Cancer: ABBV-400 Treatment Study

We are studying a new drug, ABBV-400, combined with standard treatments for adults with advanced colorectal cancer. The goal is to assess its safety and effectiveness in patients who have already been treated.

Metastatic Colorectal CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Cholestyramine for Obese Women: Pollutant Levels Study

We are exploring how cholestyramine treatment impacts harmful pollutant levels in obese women who may undergo bariatric surgery. This study aims to understand its effects before and after the surgery.

Epidermolysis Bullosa≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyEndocrinologyInternal Medicine

Innovative Cell Therapy for Autoimmune Xerostomia

We are studying a new treatment using fat-derived cells for patients with autoimmune xerostomia. The goal is to see if it can improve symptoms and is safe to use.

Autoimmune Xerostomia1-2 yearsSafety phase (I)Efficacy phase (II)OtolaryngologyRheumatology

Pyridoxine for Primary Sclerosing Cholangitis

We are studying whether pyridoxine can lower liver enzyme levels in people with primary sclerosing cholangitis. The trial will also look at its effects on vitamin B6 levels, liver function, and quality of life.

Primary Sclerosing Cholangitis≤3 monthsEfficacy phase (II)Standard MedicinesGastroenterologyHepatology

Non-Small Cell Lung Cancer: Fianlimab and Cemiplimab with Chemotherapy

We are studying if adding Fianlimab to Cemiplimab and chemotherapy is safer and more effective for adults with early-stage non-small cell lung cancer that can be surgically removed. This trial will help us understand the best treatment options for these patients.

Resectable Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)16-20 visitsStandard MedicinesCost ReimbursementPartially RemoteOncology

Duchenne Muscular Dystrophy: GNT0004 Gene Therapy

We are testing a new gene therapy for boys with Duchenne Muscular Dystrophy who can walk. The study aims to find the right dose and evaluate the therapy's safety and effectiveness compared to a placebo.

Duchenne Muscular DystrophySafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineNeurologyPediatrics

Combination Therapies for Advanced Esophageal Cancer

We are studying new treatment combinations for patients with advanced esophageal cancer who have already been treated with PD-1/PD-L1 therapies. The aim is to evaluate their safety and how well they work in shrinking tumors and improving survival.

Advanced Esophageal Squamous Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteOncology

Atopic Dermatitis: PF-07275315 and PF-07264660

We are investigating two new treatments for adults with moderate to severe atopic dermatitis. The study aims to see if they are more effective than a placebo in reducing eczema symptoms.

Atopic Dermatitis1-2 yearsEfficacy phase (II)6-10 visitsCost ReimbursementPartially RemoteAllergologyDermatology

Multiple Myeloma: Innovative Treatment Approaches

We are studying new methods to monitor multiple myeloma in patients who have not yet been treated. This trial compares different treatment combinations, including a stem cell transplant, to see which is more effective.

Multiple Myeloma6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Type 1 Diabetes: New Cell Therapy for Children

We are studying a new treatment combining cell therapy and an antibody for children with early-stage type 1 diabetes. The goal is to see if this approach can help delay the onset of diabetes symptoms.

Prediabetes>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesEndocrinologyInfectious DiseasesPediatrics

Acute Myeloid Leukemia: MP0533 Treatment Study

We are testing a new drug, MP0533, for patients with acute myeloid leukemia or myelodysplastic syndrome. The study aims to evaluate its safety and how well it may work against these blood cancers.

Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)Safety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology